Why Is Telix Pharma Stock Soaring Tuesday?

Benzinga04-08

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares climbed Tuesday after the company reported solid revenue growth and continued progress across its therapeutics pipeline.

Wedbush analyst David Nierengarten reiterated an Outperform rating on the stock and maintained a $22 price target, underscoring confidence in Telix’s growth trajectory.

Growth Fueled By Imaging Demand

The move follows a business update highlighting strong momentum in Telix’s Precision Medicine unit, driven by rising adoption of its imaging portfolio.

In its first-quarter 2026 update, Telix said U.S. dose volumes rose 5% quarter over quarter, reflecting sustained demand for key products, including Illuccix and Gozellix.

Revenue Growth And Guidance Reaffirmed

The radiopharmaceuticals company reported first-quarter interim sales of $230 million, up 11% sequentially. Precision Medicine revenue came in at $186 million, marking a 16% quarter-over-quarter increase.

Telix reaffirmed its fiscal 2026 revenue outlook of $950 million to $970 million, supported by ongoing product sales in approved markets and a full-year contribution from RLS.

The company also maintained its R&D spending guidance of $200 million to $240 million, tied to advancing global commercial and clinical milestones.

Pipeline Progress Adds Confidence

In March, Telix announced that Part 1 of its ProstACT global Phase 3 study met its primary endpoints. The study showed TLX591-Tx demonstrated an acceptable safety and tolerability profile, supporting its therapeutic potential.

Analyst Positioning Remains Constructive

Telix currently carries a consensus Buy rating with an average price target of $21.63.

Recent analyst actions include:

Wedbush: Outperform, $22 target (April 7)
H.C. Wainwright & Co.: Buy, $20 target (April 7)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Telix Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

Value: Weak (Score: 13.64) — Trading at a steep premium relative to peers.
Momentum: Bullish (Score: 83/100) — Stock is outperforming the broader market.

The Verdict: Telix Pharmaceuticals’ Benzinga Edge signal reveals a growth-heavy profile, with strong momentum but a weak value ranking, indicating potential overvaluation relative to its peers.

TLX Price Action: Telix Pharmaceuticals shares were up 5.72% at $9.610 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.